Report of Foreign Issuer (6-k)
September 25 2020 - 4:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2020 (No. 2)
Commission File Number 001-37846
CELLECT BIOTECHNOLOGY LTD.
(Translation of registrant’s name
into English)
23 Hata’as
Street
Kfar Saba, Israel
44425
(Address of principal
executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On September 25, 2020, Cellect Biotechnology
Ltd. (the “Company”) announced that on November 1, 2020, the Company will hold its annual general meeting at the offices
of Doron, Tikotzky, Kantor, Gutman, Nass & Amit Gross, at B.S.R 4 Tower, 33rd Floor, 7 Metsada Street, Bnei Brak, Israel at
2:00 p.m. Israel Standard Time. The Company is providing with this Form 6-K report as exhibits the following documents:
|
1.
|
A copy of the Notice and
Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders, describing the proposals to be voted
upon at the meeting, the procedure for voting in person or by proxy at the meeting, and various other details relating to the
meeting, is attached hereto as Exhibit 99.1;
|
|
2.
|
A form of Proxy Card, whereby
holders of ordinary shares of the Company may vote at the meeting without attending the meeting in person, is attached hereto
as Exhibit 99.2; and
|
|
3.
|
A form of Voting Instruction
Card, whereby holders of American Depositary Shares of the Company may instruct Bank of New York Mellon to vote at the meeting,
is attached hereto as Exhibit 99.3.
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
CELLECT BIOTECHNOLOGY, LTD.
|
|
|
|
By:
|
/s/ Eyal Leibovitz
|
|
Name:
|
Eyal Leibovitz
|
|
Title:
|
Chief Financial Officer
|
|
|
|
Date: September 25, 2020
|
|
2
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From May 2024 to Jun 2024
Cellect Biotechnology (NASDAQ:APOP)
Historical Stock Chart
From Jun 2023 to Jun 2024